利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.018 秒)

    PHARMACEUTICAL COMPOSITION TO PREVENT AND TREAT ALZHEIMER'S DISEASE COMPRISING GCP II MUTANT
    5.
    发明申请
    PHARMACEUTICAL COMPOSITION TO PREVENT AND TREAT ALZHEIMER'S DISEASE COMPRISING GCP II MUTANT 审中-公开
    用于预防和治疗包含GCP II突变体的阿尔茨海默病的药物组合物

    公开(公告)号：US20130089536A1

    公开(公告)日：2013-04-11

    申请号：US13647169

    申请日：2012-10-08

    申请人： Korea Center For Disease Control and Prevention

    发明人： Hyunyoung KIM ,  Suk Kyung LEE ,  Sang Ick PARK ,  Sangmee AHN

    IPC分类号： A61K38/48 ,  A61P25/28 ,  A61P25/00 ,  C40B30/04 ,  C12Q1/68 ,  G01N33/573 ,  C12Q1/37 ,  G01N27/62 ,  A61K31/711 ,  A61P7/02

    CPC分类号： A61K38/4813 ,  C12Y304/17021 ,  G01N33/5023 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821

    摘要： The present invention relates to a GCP II (glutamate carboxypeptidase II) mutant (K699S) having the activity of inhibiting glutamate production and the activity of cleavaging β-amyloid, and to a pharmaceutical composition for the prevention and treatment of a disease selected from the group consisting of amyloidosis, Alzheimer's disease, Down syndrome accompanying Alzheimer's disease, stroke, dementia, Huntington's disease, Pick's disease, and Creutzfeldt-Jakob disease comprising the GCP II mutant (K699S) as an active ingredient. The GCP II (glutamate carboxypeptidase II) mutant (K699S) demonstrates not only excellent Aβ cleavage activity compared with the wild type GCP II but also excellent activity of inhibiting glutamate production, unlike the wild type GCP II, so that the mutant has been confirmed to have higher effect and stability than the wild type, suggesting that the GCP II mutant can be effectively used for the prevention or treatment of neurodegenerative diseases.

    摘要翻译： 本发明涉及具有抑制谷氨酸生产活性和切割活性的淀粉样蛋白的GCP II（谷氨酸羧肽酶II）突变体（K699S），以及用于预防和治疗选自以下的疾病的药物组合物： 包括由GCP II突变体（K699S）作为活性成分的淀粉样变性，阿尔茨海默氏病，唐氏综合征伴随阿尔茨海默氏病，中风，痴呆，亨廷顿舞蹈病，皮克病和克雅氏病。 GCP II（谷氨酸羧肽酶II）突变体（K699S）不仅表现出优异的A＆bgr; 与野生型GCP II相比，裂解活性与野生型GCP II相比还具有优异的抑制谷氨酸生产活性，与野生型GCP II不同，突变体已被证实具有比野生型更高的效果和稳定性，这表明GCP II突变体可以 有效地用于预防或治疗神经退行性疾病。

    MONOCLONAL ANITBODY FOR SPIKE PROTEIN OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS AND USE THEREOF
    7.
    发明申请
    MONOCLONAL ANITBODY FOR SPIKE PROTEIN OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS AND USE THEREOF 有权

    公开(公告)号：US20210355193A1

    公开(公告)日：2021-11-18

    申请号：US16641580

    申请日：2018-08-23

    申请人： KOREA (CENTER FOR DISEASE CONTROL AND PREVENTION) ,  NIH Office of Tech Transfer

    发明人： Hansaem Lee ,  Janghoon Choi ,  Sungsoon Kim ,  Lingshu Wang ,  Barney Graham ,  John Mascola

    IPC分类号： C07K16/10 ,  G01N33/569

    摘要： The present invention relates to monoclonal antibodies for a spike protein of the Middle East respiratory syndrome coronavirus (MERS-CoV), and a use thereof. Particularly, monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the Si domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV. Also, the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV, and the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV. Further, the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.

    Diagnosis of alzheimer's disease using Aβ22(pE)-42 peptide
    9.
    发明授权
    Diagnosis of alzheimer's disease using Aβ22(pE)-42 peptide 有权
    使用A＆Bgr 22（pE）-42肽诊断阿尔茨海默病

    公开(公告)号：US08679768B2

    公开(公告)日：2014-03-25

    申请号：US13645741

    申请日：2012-10-05

    申请人： Korea Center for Disease Control and Prevention

    发明人： Young-Youl Kim ,  Seungwoo Kim ,  Hyo-Soon Cheon ,  Sang Ick Park

    IPC分类号： G01N33/533 ,  G01N33/534 ,  G01N33/535 ,  G01N33/536 ,  G01N33/539

    CPC分类号： C07K14/4711 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2814 ,  G01N2800/2821

    摘要： The present inventors screened peptides having a specific sequence specifically binding to amyloid-beta antibody and accordingly confirmed that Aβ22(pE)-42 peptide showed higher reactivity to amyloid-beta antibody in serum of Alzheimer's disease patients. Therefore, the said Aβ22(pE)-42 peptide can be used as an active ingredient for the kit for diagnosing dementia and thus it can be said that the peptide can be effectively used for the diagnosis of dementia whose early diagnosis is hardly possible.

    摘要翻译： 本发明人筛选了具有与淀粉样蛋白-β抗体特异性结合的特异性序列的肽，因此证实A＆Bgr 22（pE）-42肽对阿尔茨海默病患者血清中的淀粉样蛋白-β抗体具有更高的反应性。 因此，所述A＆bgr22（pE）-42肽可用作用于诊断痴呆症的试剂盒的有效成分，因此可以说该肽可有效用于早期诊断几乎不可能的痴呆诊断 。